FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005356742> ?p ?o ?g. }

• W3005356742 abstract "To compare mortality after treatment of superficial femoral-popliteal artery disease with paclitaxel and nonpaclitaxel devices using a multicenter vascular registry.Patients (N=8376) undergoing endovascular treatment of superficial femoral-popliteal artery disease in the Society for Vascular Surgery Vascular Quality Initiative were studied from October 2016 to December 2017. One-year mortality was compared between 3 groups; plain balloon angioplasty (N=2104) versus paclitaxel-coated balloon angioplasty (N=3543), bare-metal stenting (N= 2045) versus paclitaxel-eluting stents (N=684), and combined paclitaxel versus nonpaclitaxel devices. Mortality rates with hazard ratios (HR) and 95% CI were compared in unadjusted and propensity-matched cohorts and illustrated by Kaplan-Meier analysis with subgroup analysis for intermittent claudication, chronic limb-threatening ischemia, and secondary interventions.In propensity-matched analyses, mortality was similar after plain balloon angioplasty (12.6%) and paclitaxel-coated balloon angioplasty (9.6%; HR=0.84 [95% CI, 0.66-1.06], P=0.14). In propensity-matched groups, mortality was similar after bare-metal stenting (9.8%) and paclitaxel-eluting stenting (8.8%; HR=0.93 [95% CI, 0.62-1.41], P=0.75). In the combined, matched analysis mortality was significantly lower in the paclitaxel device group (8.5%) compared with the nonpaclitaxel device group (11.5%; HR=0.82 [95% CI, 0.68-0.98], P=0.03). Secondary interventions were similar after nonpaclitaxel (N=1113/4149, 26.8%) and paclitaxel device use (N=1113/4227, 26.3%). For intermittent claudication, mortality was lower after paclitaxel device use (1.6%) compared with nonpaclitaxel devices (4.4%; adjusted HR=0.59 [95% CI, 0.39-0.89], P=0.01). For chronic limb-threatening ischemia, the mortality difference was not significant; paclitaxel (12.8%) versus nonpaclitaxel devices (15.5%; adjusted HR=0.85 [95% CI, 0.72-1.00], P=0.05).At 1 year, mortality was similar if not lower after treatment of femoral-popliteal occlusive disease with paclitaxel versus nonpaclitaxel devices. This work highlights the potential use of the Society for Vascular Surgery Vascular Quality Initiative for surveillance of the safety of new peripheral arterial devices." @default.
• W3005356742 created "2020-02-14" @default.
• W3005356742 creator A5006684960 @default.
• W3005356742 creator A5015697849 @default.
• W3005356742 creator A5032316277 @default.
• W3005356742 creator A5043383232 @default.
• W3005356742 creator A5043384115 @default.
• W3005356742 creator A5044493690 @default.
• W3005356742 creator A5056335297 @default.
• W3005356742 creator A5065001569 @default.
• W3005356742 creator A5073942058 @default.
• W3005356742 date "2020-02-01" @default.
• W3005356742 modified "2023-09-25" @default.
• W3005356742 title "Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative" @default.
• W3005356742 cites W114852567 @default.
• W3005356742 cites W122961614 @default.
• W3005356742 cites W1844006054 @default.
• W3005356742 cites W1944762875 @default.
• W3005356742 cites W1977671695 @default.
• W3005356742 cites W2001506071 @default.
• W3005356742 cites W2044021276 @default.
• W3005356742 cites W2118501388 @default.
• W3005356742 cites W2155014613 @default.
• W3005356742 cites W2165100349 @default.
• W3005356742 cites W2291242522 @default.
• W3005356742 cites W2295508527 @default.
• W3005356742 cites W2529833515 @default.
• W3005356742 cites W2546593435 @default.
• W3005356742 cites W2739447339 @default.
• W3005356742 cites W2741019994 @default.
• W3005356742 cites W2753407454 @default.
• W3005356742 cites W2782950511 @default.
• W3005356742 cites W2784684720 @default.
• W3005356742 cites W2802562571 @default.
• W3005356742 cites W2803839738 @default.
• W3005356742 cites W2808510582 @default.
• W3005356742 cites W2903350476 @default.
• W3005356742 cites W2913667111 @default.
• W3005356742 cites W2919789849 @default.
• W3005356742 cites W2927627017 @default.
• W3005356742 cites W2946328497 @default.
• W3005356742 cites W2947332499 @default.
• W3005356742 cites W3144215568 @default.
• W3005356742 doi "https://doi.org/10.1161/circinterventions.119.008528" @default.
• W3005356742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32069110" @default.
• W3005356742 hasPublicationYear "2020" @default.
• W3005356742 type Work @default.
• W3005356742 sameAs 3005356742 @default.
• W3005356742 citedByCount "37" @default.
• W3005356742 countsByYear W30053567422020 @default.
• W3005356742 countsByYear W30053567422021 @default.
• W3005356742 countsByYear W30053567422022 @default.
• W3005356742 countsByYear W30053567422023 @default.
• W3005356742 crossrefType "journal-article" @default.
• W3005356742 hasAuthorship W3005356742A5006684960 @default.
• W3005356742 hasAuthorship W3005356742A5015697849 @default.
• W3005356742 hasAuthorship W3005356742A5032316277 @default.
• W3005356742 hasAuthorship W3005356742A5043383232 @default.
• W3005356742 hasAuthorship W3005356742A5043384115 @default.
• W3005356742 hasAuthorship W3005356742A5044493690 @default.
• W3005356742 hasAuthorship W3005356742A5056335297 @default.
• W3005356742 hasAuthorship W3005356742A5065001569 @default.
• W3005356742 hasAuthorship W3005356742A5073942058 @default.
• W3005356742 hasBestOaLocation W30053567421 @default.
• W3005356742 hasConcept C126322002 @default.
• W3005356742 hasConcept C139059822 @default.
• W3005356742 hasConcept C141071460 @default.
• W3005356742 hasConcept C164705383 @default.
• W3005356742 hasConcept C207103383 @default.
• W3005356742 hasConcept C2776694085 @default.
• W3005356742 hasConcept C2777209855 @default.
• W3005356742 hasConcept C2777292972 @default.
• W3005356742 hasConcept C2777303625 @default.
• W3005356742 hasConcept C2777466421 @default.
• W3005356742 hasConcept C2778283817 @default.
• W3005356742 hasConcept C2778583881 @default.
• W3005356742 hasConcept C2778963770 @default.
• W3005356742 hasConcept C2779723990 @default.
• W3005356742 hasConcept C2779881954 @default.
• W3005356742 hasConcept C2780326628 @default.
• W3005356742 hasConcept C3018348675 @default.
• W3005356742 hasConcept C44249647 @default.
• W3005356742 hasConcept C71924100 @default.
• W3005356742 hasConceptScore W3005356742C126322002 @default.
• W3005356742 hasConceptScore W3005356742C139059822 @default.
• W3005356742 hasConceptScore W3005356742C141071460 @default.
• W3005356742 hasConceptScore W3005356742C164705383 @default.
• W3005356742 hasConceptScore W3005356742C207103383 @default.
• W3005356742 hasConceptScore W3005356742C2776694085 @default.
• W3005356742 hasConceptScore W3005356742C2777209855 @default.
• W3005356742 hasConceptScore W3005356742C2777292972 @default.
• W3005356742 hasConceptScore W3005356742C2777303625 @default.
• W3005356742 hasConceptScore W3005356742C2777466421 @default.
• W3005356742 hasConceptScore W3005356742C2778283817 @default.
• W3005356742 hasConceptScore W3005356742C2778583881 @default.
• W3005356742 hasConceptScore W3005356742C2778963770 @default.
• W3005356742 hasConceptScore W3005356742C2779723990 @default.
• W3005356742 hasConceptScore W3005356742C2779881954 @default.
• W3005356742 hasConceptScore W3005356742C2780326628 @default.
• W3005356742 hasConceptScore W3005356742C3018348675 @default.

• next